Unfortunately, we do not have the information regarding molecular features of the DLBCL – or other lymphomas – in our current retrospective cohort, apart from a single negative test for BCL6, C-MYC, BCL2 and p53 gene defects. This evidence concerns the gene TP53 and diffuse large B-cell lymphoma.